Literature DB >> 2949824

Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocin.

B Eriksson, K Oberg, T Curstedt, A Hemmingsson, H Johansson, E Lindh, P G Lindgren, K A Thuomas, E Wilander, G Akerström.   

Abstract

Three patients with advanced adrenocortical carcinoma were treated with a combination of intermittent streptozocin and continuous o,p'DDD. Two patients were treated preoperatively and the primary tumors, initially considered as inoperable, could be resected after 19 and 5.5 months, respectively. In the patient with the longer treatment (35 months), lung and lymph node metastases disappeared and she has no evidence of recurrent disease 6.5 years after start of therapy. One patient was followed by magnetic resonance imaging (MRI) and urinary steroid secretion. The MRI gave a good visualization of the tumor. Measurements of relaxation times showed a significant decrease in T1 values. The urinary steroid profile showed an increased secretion of 3 beta-hydroxy-5-ene steroids and tetrahydro-11-deoxy-cortisol. Treatment with streptozocin and o,p'DDD initially increased 16-oxygenation of dehydroepiandrosterone and androst-5-en-3 beta,17 beta-diol, followed by a decrease in the secretion of all urinary steroids. The third patient received postoperative treatment with no effect on metastatic disease in the lungs, she died 9 months after start of treatment. The therapeutic approach with the combination regimen of streptozocin and o,p'DDD pretreatment plus aggressive surgery has to be further evaluated, as well as MRI and urinary steroid profile as methods to monitor the effect of therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949824     DOI: 10.1002/1097-0142(19870415)59:8<1398::aid-cncr2820590803>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  [Systemic therapy of malignant adrenal tumors].

Authors:  M Horstmann; A S Merseburger; A Stenzl; M Kuczyk
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Adrenocorticolytic DDT-metabolites: studies in mink, Mustela vison and otter, Lutra lutra.

Authors:  C J Jönsson; B O Lund; I Brandt
Journal:  Ecotoxicology       Date:  1993-03       Impact factor: 2.823

Review 3.  Diagnosis and management of adrenal cortical carcinoma.

Authors:  Brant R Fulmer
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

4.  Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.

Authors:  Tanweera S Khan; Anders Sundin; Claes Juhlin; Erik Wilander; Kjell Oberg; Barbro Eriksson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

Authors:  H R Haak; J Hermans; C J van de Velde; E G Lentjes; B M Goslings; G J Fleuren; H M Krans
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.